Company profile
Blueberry Therapeutics Limited
Blueberry Therapeutics Modern Drug Discovery & Development
Blueberry Therapeutics is a drug discovery and development company developing innovative nanomedicines in dermatology
Company events
Reference milestones and recent Companies House filing stream events.
Liquidation Voluntary Creditors Return Of Final Meeting
InsolvencyLIQ14 | Transaction MzUyNjAwNzg4MGFkaXF6a2N4 | Paper/PDF filed
Published 23 Jun 2026 23:03
Accounts due
Accounts DueNext accounts due date
Confirmation statement due
Confirmation DueNext confirmation statement due date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Development of a coupled inactivating transport medium and RNA purification protocol for SARS-CoV-2
1 Aug 2020 to 30 Sep 2021
The standard method for detecting SARS-CoV-2, the virus responsible for causing COVID-19, is called "RT-PCR" (reverse transcription, polymerase chain reaction). RT-PCR works by directly detecting the virus genetic material in patient samples and as such it requires the virus genetic material (its genome) to be intact in these samples in order to work. Bec...
Assessment of novel nanoformulations for the treatment of acne
1 Jul 2017 to 31 Mar 2018
Acne is a common disease, which can turn into a serious chronic disorder leading to permanent scaring and disfigurement. The current market for acne treatments is worth approximately $2.8 billion/annum (2016) but is dominated by poorly efficacious over-the-counter treatments, which are often reformulations of the same active ingredients (e.g. benzoyl pero...
Nanoparticle Formulation for the Treatment of Tinea Pedis
1 Jun 2015 to 30 Nov 2015
Tinea pedis, also known as athlete’s foot, is a common dermatophytic infection, which is extremely difficult to eradicate. Its symptoms include pruritic, scaly soles and often painful fissures between the toes. Tinea pedis is currently treated with topical or oral antifungals, which are usually used for 1-6 weeks. However recurrences are common with up to...
Development of a new class of bacterial resistance inhibitors for the treatment of multi-drug resistant infection
1 Aug 2013 to 31 Jul 2014
The spread of multi-drug resistance (MDR) threatens to change the face of health care worldwide, crippling hospital units that rely on the ability to control infections in patients with weakened immune systems. We risk returning to a "pre-antibiotic" era unless we can develop new approaches to tackling bacterial resistance. Blueberry Therapeutics aims to ...